



Kilitch Drugs (India) Ltd.

Admin. Off. : 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400 088.
 • Tel. : +91-22-6121 4100 • Fax : +91-22-67031658
 Regd. Off. : C-301/2, M.I.D.C., T.T.C. Industrial Area, Pawane Village, Navi Mumbai - 400 705. Maharashtra
 • Tel. : +91-22-6514 4185 / 2768 0913 • Fax : +91-22-2768 0912
 & Factory • E-mail : info@kilitch.com • Website : www.kilitch.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2011								(Rs. in Lacs)	
Sr. No	PARTICULARS	Stand Alone				Consolidated		Year ended 31.03.2011 Audited	Year ended 31.03.2011 Audited
		Quarter ended 30.09.2011 Unaudited	Quarter ended 30.09.2010 Unaudited	Six Month ended on 30.09.2011 Unaudited	Six Month ended on 30.09.2010 Unaudited	Six Month ended on 30.09.2011 Unaudited	Six Month ended on 30.09.2011 Unaudited		
1	Sales & Operating Income (net)	3,281.58	3,219.28	6,311.02	6,444.84	14,589.53	6,419.19	14,630.17	
2	Other Income	21.09	5.90	25.32	5.90	28.55	25.32	21.00	
	Total	3,302.67	3,225.18	6,336.34	6,450.74	14,626.08	6,444.51	14,651.17	
3	Expenditure	(12.46)	(397.30)	(296.33)	(343.52)	(217.03)	(296.33)	(217.03)	
	a) (Increase)/Decrease in Stock-in-Trade & WIP	1,933.46	2,433.11	4,129.01	4,400.70	10,314.41	4165.37	10287.53	
	b) Consumption of materials	131.92	68.58	245.08	219.69	505.10	337.33	531.95	
	c) Employee Costs	425.59	287.73	819.15	630.99	1,784.20	870.72	1820.74	
	d) Other Expenses	17.99	120.01	121.95	196.89	372.53	121.95	357.62	
4	Interest	140.31	146.13	280.00	297.00	568.74	280.00	558.74	
5	Depreciation	665.86	566.92	1,037.48	1,048.99	1,308.13	965.47	1,311.62	
6	Profit before tax	133.84	58.92	207.91	155.00	262.07	207.91	262.82	
7	Tax Expense	532.02	508.00	829.57	893.99	1,046.06	757.56	1,048.80	
8	Net Profit						0.00		
9	Paid up Equity share Capital (face value of Rs.10 per share)	1,323.18	1,320.21	1,323.18	1,320.21	1,323.18	1,323.18	1,323.18	
10	Reserves excluding Revaluation Reserves	-	-	-	-	-	-	-	
11	Earnings Per Share (EPS)								
	- Basic EPS(Rs.)	4.02	3.85	6.27	6.77	7.91	5.73	7.92	
	- Diluted EPS(Rs.)	4.02	3.75	6.27	6.61	7.73	5.73	7.74	
12	Public Shareholding								
	- Numbers of Shares	4706393	4670487	4706393	4670487	4706393	4706393	4706393	
	- Percentage of Shareholding	35.57	35.38	35.57	35.38	35.57	35.57	35.57	
13	Promoters and Promoter group shareholding								
	a) Pledge Encumbered								
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil	N/A	
	- Percentage of Shares as a % of the total shareholding of Promoter and Promoter group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
	- Percentage of Shares as a % of the total share capital of company	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
	b) Non-Encumbered								
	- Number of Shares	8525435	8531635	8525435	8531635	8525435	8525435	8525435	
	- Percentage of Shares as a % of the total shareholding of Promoter and Promoter group	100.00	100.00	100.00	100.00	100.00	100.00	100	
	- Percentage of Shares as a % of the total share capital of company	64.43	64.62	64.43	64.62	64.43	64.43	64.43	

Statement of Assets and Liabilities As on 30th September 2011		
	Stand Alone	Consolidated
Shareholders' Funds		
Share Capital	1323.18	1323.18
Reserves and Surplus	7911.59	7849.43
Minority Interest		135.66
Loan Funds		
Secured Loan	4954.50	4962.59
Total	14189.27	14270.86
Fixed Assets		
Gross Block	7557.62	7570.49
Less: Depreciation	3511.46	3511.46
Net Block	4,046.16	4,059.03
Capital Work in Progress	5017.94	5017.94
	9,064.10	9,076.97
Deferred Tax Assets (net)	746.66	746.66
Investments	215.07	21.83
Current Assets, Loans and Advances		
Inventories	1862.66	1889.45
Sundry Debtors	5944.88	6003.55
Cash and Bank Balances	311.78	316.83
Loans and Advances	-313.01	-78.89
	7,806.31	8,130.94
Less: Current Liabilities & Provisions		
Current Liabilities	2176.77	2216.99
Provisions	1480.81	1503.25
	3657.58	3720.24
	4,148.73	4,410.70
Miscellaneous Expenditure (To the extent not written off or adjusted)	14.70	14.70
Total	14189.27	14270.86

Notes:

- The above results after being reviewed by the Audit Committee, have been approved and taken on record by the Board of Directors at its meeting held on 14.11.2011, and are subject to Limited Review by the Auditors.
- Investors complaints for the quarter (In Nos.): o/s as on 01.07.11 - Nil; Received during the Qtr. - 7; Resolved during the Qtr. -7; o/s as On 30.09.2011 - Nil
- The prior period figures have been regrouped / reclassified, wherever required.
- The Company has only one Primary Reportable Segment viz. 'Pharmaceuticals'

By and on Behalf of the Board
For Kilitch Drugs (India) Ltd.

Bhavini M. Mehta

BHAVINI M. MEHTA
DIRECTOR

Place : Mumbai
Date : 14.11.2011

